Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors

Clinical Journal of Oncology Nursing

Volumn 15, Issue 5, 2011, Pages

  Pilotte, Amy Potter ^a   Hohos, Melissa Beth ^b   Polson, Kathleen M O ^a   Huftalen, Tarsha Marie ^a   Treister, Nathaniel ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b St Anne's Hospital   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HUMAN; NURSING; NURSING METHODOLOGY RESEARCH; ONCOLOGY NURSING; PATIENT EDUCATION; PHASE 1 CLINICAL TRIAL (TOPIC); STOMATITIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; NURSING METHODOLOGY RESEARCH; ONCOLOGIC NURSING; PATIENT EDUCATION AS TOPIC; STOMATITIS; TOR SERINE-THREONINE KINASES;

EID: 80053265601     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/11.CJON.E83-E89     Document Type: Article

References (36)

1. Atkins, M.B., Hidalgo, M., Stadler, W.M., Logan, T.F., Dutcher, J.P., & Hudes, G.R. (2004). Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology, 22, 909-918. doi:10.1200/JCO.2004.08.185
2. Bensinger, W., Schubert, M., Ang, K.K., Brizel, D., Brown, E., Eilers, J.G.,... Trotti, A.M., III. (2008). NCCN Task Force Report: Prevention and management of mucositis in cancer care. Journal of the National Comprehensive Cancer Network, 6(1, Suppl.), S1-S21.
3. Bjornsti, M.A., & Houghton, P.J. (2004). The TOR pathway: A target for cancer therapy. Nature Reviews. Cancer, 4, 335-348. doi:10.1038/nrc1362
4. Brown, C.G., & Wingard, J. (2004). Clinical consequences of oral mucositis. Seminars in Oncology Nursing, 20(1), 16-21. doi:10.1053/j.soncn.2003.10.004
5. Buckner, J.C., Forouzesh, B., Erlichman, C., Hidalgo, M., Boni, J.P.,... Rowinsky, E.K. (2010). Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Investigational New Drugs, 28, 334-342. doi:10.1007/s10637-009-9257-1
6. Carraway, H., & Hidalgo, M. (2004). New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Research, 6, 219-224. doi:10.1186/bcr927
7. Chan, S., Scheulen, M.E., Johnston, S., Mross, K., Cardoso, F.,... Moore, L. (2005). Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. Journal of Clinical Oncology, 23, 5314-5322. doi:10.1200/JCO.2005.66.130
8. Chitnis, M.M., Yuen, J.S., Protheroe, A.S., Pollak, M., & Macaulay, V.M. (2008). The type 1 insulin-like growth factor receptor pathway. Clinical Cancer Research, 14, 6364-6370. doi:10.1158/1078-0432.CCR-07-4879
9. Chuang, P., & Langone, A.J. (2007). Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. American Journal of Transplantation, 7, 714-717. doi:10.1111/j.1600-6143.2006.01678.x
10. Fasolo, A., & Sessa, C. (2008). mTOR inhibitors in the treatment of cancer. Expert Opinion on Investigational Drugs, 17, 1717-1734. doi:10.1517/13543784.17.11.1717
11. Hidalgo, M., Buckner, J.C., Erlichman, C., Pollack, M.S., Boni, J.P.,... Rowinsky, E.K. (2006). A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clinical Cancer Research, 12, 5755-5763. doi:10.1158/1078-0432.CCR-06-0118
12. Hsieh, A.C., & Moasser, M.M. (2007). Targeting HER proteins in cancer therapy and the role of the non-target HER3. British Journal of Cancer, 97, 453-457. doi:10.1038/sj.bjc.6603910
13. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A.,... Motzer, R.J. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine, 356, 2271-2281. doi:10.1056/NEJMoa066838
14. Kerr, A.R., & Ship, J.A. (2003). Management strategies for HIV-associated aphthous stomatitis. American Journal of Clinical Dermatology, 4, 669-680. doi:10.2165/00128071-200304100-00002
15. MacDonald, A.S. (2001). A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation, 71, 271-280. doi:10.1097/00007890-200101270-00019
16. Mahé, E., Morelon, E., Lechaton, S., Sang, K.H., Mansouri, R., Ducasse, M.F.,... Bodemer, C. (2005). Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation, 79, 476-482.
17. Mita, M.M., Britten, C.D., Poplin, E., Tap, W.D., Carmona, A., Yonemoto, L.,... Tolcher, A.W. (2008). Deforolimus trial 106-A phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669) [Abstract 3509.]. http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32547
18. Mita, M.M., Mita, A.C., Chu, Q.S., Rowinsky, E.K., Fetterly, G.J., Goldston, M.,... Tolcher, A.W. (2008). Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. Journal of Clinical Oncology, 26, 361-367. doi:10.1200/JCO.2007.12.0345
19. Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S.,... Ravaud, A. (2008). Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet, 372, 449-456. doi:10.1016/S0140-6736(08)61039-9
20. Motzer, R.J., Hudes, G.R., Curti, B.D., McDermott, D.F., Escudier, B.J., Negrier, S.,... Dutcher, J.P. (2007). Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. Journal of Clinical Oncology, 25, 3958-3964. doi:10.1200/JCO.2006.10.5916
21. National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). Retrieved from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
22. National Institutes of Health. (2011). Ridaforolimus in treatment of sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus). Retrieved from http://clinicaltrials.gov/ct2/show/NCT00538239?term=00538239&rank=1
23. Preshaw, P.M., Grainger, P., Bradshaw, M.H., Mohammad, A.R., Powala, C.V., & Nolan, A. (2007). Subantimicrobial dose doxycycline in the treatment of recurrent oral aphthous ulceration: A pilot study. Journal of Oral Pathology and Medicine, 36, 236-240. doi:10.1111/j.1600-0714.2007.00507.x
24. Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J.,... Armand, J.P. (2004). Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. Journal of Clinical Oncology, 22, 2336-2347. doi:10.1200/JCO.2004.08.116
25. Sankhala, K., Mita, A., Kelly, K., Mahalingam, D., Giles, F., & Mita, M. (2009). The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Targeted Oncology, 4, 135-142.
26. Saunders, R.N., Metcalfe, M.S., & Nicholson, M.L. (2001). Rapamycin in transplantation: A review of the evidence. Kidney International, 59(1), 3-16. doi:10.1046/j.1523-1755.2001.00460.x
27. Scully, C. (2006). Clinical practice. Aphthous ulceration. New England Journal of Medicine, 355, 165-172. doi:10.1056/NEJMcp054630
28. Scully, C., Gorsky, M., & Lozada-Nur, F. (2003). The diagnosis and management of recurrent aphthous stomatitis: A consensus approach. Journal of the American Dental Association, 134, 200-207.
29. Scully, C., & Porter, S. (2008). Oral mucosal disease: Recurrent aphthous stomatitis. British Journal of Oral and Maxillofacial Surgery, 46, 198-206. doi:10.1016/j.bjoms.2007.07.201
30. Shaw, R.J., & Cantley, L.C. (2006). Ras, PI(3)K, and mTOR signalling controls tumour cell growth. Nature, 441, 424-430. doi:10.1038/nature04869
31. Sonis, S., Treister, N., Chawla, S., Demetri, G., & Haluska, F. (2010). Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer, 116, 210-215.
32. Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K.,... Baselga, J. (2008). Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. Journal of Clinical Oncology, 26, 1603-1610. doi:10.1200/JCO.2007.14.5482
33. van Gelder, T., ter Meulen, C.G., Hené, R., Weimar, W., & Hoitsma, A. (2003). Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation, 75, 788-791. doi:10.1097/01.TP.0000056639.74982.F9
34. Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005). mTOR-targeted therapy of cancer with rapamycin derivatives. Annals of Oncology, 16, 525-537. doi:10.1093/annonc/mdi113
35. Warino, L., & Libecco, J. (2006). Cutaneous effects of sirolimus in renal transplant recipients. Journal of Drugs in Dermatology, 5, 273-274.
36. Yuan, R., Kay, A., Berg, W.J., & Lebwohl, D. (2009). Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy. Journal of Hematology and Oncology, 2, 45. doi:10.1186/1756-8722-2-45